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Telogen effluvium (TE) is characterized by diffuse hair shedding 2-3 months after a
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infected with the virus were under immense psychosocial and physiologic stress. We

stressor, and COVID-19 infection is potentially one such stressor. Those who were
retrospectively reviewed electronic medical records of 552 patients who were evaluated by a Henry Ford Health System dermatologist between February 2020 and
September 2020 and had a diagnosis of COVID-19 infection. Ten patients were identified with TE attributed to COVID-19 infection and described their presentations as
a case series. For the ten patients selected, the mean age was 48.5 years old and
90% were female. Six of the patients were Black, one Middle Eastern, and three
White. On average, the hair shedding began 50 days after the first symptom of
COVID-19 infection. About 80% of these patients were treated with antibiotics, systemic corticosteroids, and/or hydroxychloroquine for their COVID-19 infection and
70% were hospitalized. The presentations of these patients suggest that COVID-19
infection may be a significant trigger of TE. TE caused by hydroxychloroquine,
azithromycin or other medications cannot be ruled out, and the global pandemic itself
is a source of psychosocial stress. Further studies will be needed to understand the
long-term prevalence and prognosis of TE associated with COVID-19 infection.
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I N T RO DU CT I O N

sequelae. Proinflammatory cytokines are released and anticoagulation mechanisms are impaired, which may provoke TE via

Telogen effluvium (TE) is characterized by diffuse hair shedding

the systemic inflammatory response and/or microthrombi in the hair

2-3 months after a stressor.1 The precipitating event causes prema-

follicles.5

ture termination of the anagen phase and subsequent transition to

Henry Ford Hospital is an urban academic center located in

the catagen and telogen phases, resulting in hair shedding. TE is usu-

Detroit, Michigan, with satellite hospitals and clinics throughout

ally self-limited; acute TE typically resolves within 6 months of

Southeastern and South-central Michigan. During the Spring of

onset and is not a scarring alopecia.2,3 Stressors that can cause TE

2020 at the onset of the pandemic, Detroit had a high incidence

include pregnancy, psychological trauma, illness, hospitalization,

of COVID-19 infections. At Henry Ford Hospital, 15 345 patients

surgery, malnutrition, and medications. The COVID-19 pandemic

were tested via polymerase chain reaction for SARS-CoV-2

is associated with these stressors; those who were infected with

infection between February 1 and April 18, 2020, and 38.3% of

the virus were under immense psychosocial and physiologic stress.4

those patients were positive.6 Here, we present a case series that

The body responds to SARS-CoV-2 infection by creating a

suggests that COVID-19 infection and associated stressors can

proinflammatory state, which leads to tissue damage and other

induce TE.

Dermatologic Therapy. 2021;e14761.
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Male

Black

Female White

Female Black

Female Black

Female Black

Female Black

Female Black

Female White

Female White

90 days

60 days

30 days

30 days

60 days

60 days

30 days

21 days

90 days

Female Middle
30 days
Eastern

Yes

Yes

No

Yes

No

Yes

Yes

Yes

No

Yes

Onset related to COVID- Hospitalized for
19 infection
COVID-19

Post-inflammatory hyperpigmentation

N/A-virtual visit

Diffuse hair thinning, positive telogen
hair pull test

Diffuse hair thinning, positive telogen
hair pull test

Diffuse hair thinning

Positive telogen hair pull test

N/A-virtual visit

Positive telogen hair pull test

Physical exam findings

Hydroxychloroquine, azithromycin,
methylprednisolone

Diffuse hair thinning, miniaturization at
crown, negative telogen hair pull test

Hydroxychloroquine, methylprednisolone, Thinning of frontal scalp and vertex,
prednisone, antibiotics
negative telogen hair pull test

Supportive

Antibiotics

Supportive

Hydroxychloroquine, methylprednisolone

Hydroxychloroquine, antibiotics

Hydroxychloroquine, azithromycin

Azithromycin

Azithromycin, ceftriaxone

Treatment of COVID-19 infection

Summary of 10 patients diagnosed with TE after COVID-19 infection

Case Age Gender Race

TABLE 1

Treatment of telogen effluvium

Minoxidil 5% solution, vitamin D
supplementation

Minoxidil 5% foam

Dandruff shampoo, clobetasol
solution, fluocinolone oil

Reassurance

Minoxidil 5% foam, iron
supplementation

Minoxidil 5% solution

Reassurance

Minoxidil 5% solution, biotin
supplementation

Reassurance

Reassurance, triamcinolone lotion
prn for itching
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METHODS

addition, the coagulation cascade becomes activated in response to
COVID-19 infection, and there is decreased concentration of antico-

Study approval was obtained from the Henry Ford Health System's

agulant proteins due to decreased production and increased con-

institutional review board (IRB approval number: 13960) and informed

sumption.5 These factors can lead to microthrombi formation, which

consent was waived. We retrospectively reviewed electronic medical

may occlude hair follicle blood supply. Microthrombi and systemic

records of 552 patients who were seen by a Henry Ford Health Sys-

inflammation represent two possible mechanisms to explain how

tem dermatologist between February 2020 and September 2020 and

COVID-19 infection could provoke TE.

had a diagnosis of laboratory-confirmed or suspected COVID-19

The mainstay of treatment for TE is correcting the underlying

infection. We reviewed the patients' demographics, dermatologic

cause and removing the inciting stressor.3 This may involve treating

manifestation, onset in relation to the first COVID-19 symptom, and

the underlying illness, discontinuing the causative medication, or cor-

treatment for the dermatologic manifestations. Prior dermatologic his-

recting nutritional deficiencies. All of these patients had since recov-

tory, COVID-19 test results, and treatment modalities of COVID-19

ered from COVID-19 infection, so the presumed primary stressor had

infection were also reviewed. Of these patients, 354 of them were

resolved; however, it is known that TE can last months or longer after

female (64.1%) and 198 were male (35.9%). The majority of patients

the initial stress. Although topical minoxidil was prescribed in 50% of

were White (262 patients, 47.5%) or Black (218 patients, 39.5%).

our patients, there is not strong evidence to suggest that it is effica-

Other races represented include Latino (15 patients, 2.7%), Middle

cious for TE.7 Educating the patient on the self-limiting natural course

Eastern (8 patients, 1.4%), East Asian (7 patients, 1.3%), and South

of the condition is a crucial component of management. The hair will

Asian (3 patients, 0.5%). The race of the remaining 39 patients was

eventually stop shedding and begin to grow back, but it may take up

unknown (7.1%). Many of the patients' dermatologic conditions were

to 18 months for hair thickness to return to baseline.1

unrelated to COVID-19 infection. The most common finding associ-

There are limitations to our study. This was a single health sys-

ated with COVID-19 infection was TE. Other dermatologic manifesta-

tem, retrospective study with a relatively small sample size. However,

tions of the virus included livedo racemosa, pernio, purpura,

to our knowledge, the only other studies investigating TE triggered by

onychomadesis, and morbilliform eruption. We identified 10 patients

COVID-19 infection are case reports and one 10-patient case

diagnosed with TE attributed to COVID-19 infection and associated

series.8,9 The case series published by Mieczkowska et al included

stressors and describe their presentations here. One additional patient

four White patients, one Black patient, and four patients of unknown

was excluded as the diagnosis of TE was made by her primary care

race.8 Compared with other studies, we had significantly more skin of

physician but was not observed by the dermatology team.

color patients, as our case series included six Black patients and one
Middle Eastern patient. It is important to note that although 39.5% of
the patients in our overall sample were Black, 60% of the patients we
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RESULTS

identified with TE after COVID-19 infection were Black. Other studies
have shown that Black patients are disproportionately affected by

We identified 10 patients that were diagnosed with TE ranging from

COVID-19 and its complications, and this discrepancy may indicate

3 weeks to 3 months after diagnosis of COVID-19 infection (Table 1).

that Black patients are at increased risk for TE after COVID-19

The mean age of the patients in this study was 48.5 years old. The

infection.10

vast majority (90%) were female. Six of the patients were Black, one

In addition, TE caused by hydroxychloroquine, azithromycin, or

Middle Eastern, and three White. On average, the hair shedding began

other medications cannot be ruled out. The global pandemic itself is

50 days after the first symptom of COVID-19 infection. About 80% of

another potential source of psychosocial stress, and there may be an

these patients were treated with antibiotics, systemic corticosteroids,

overall increase in the incidence of TE as a result.11 Nonetheless,

and/or hydroxychloroquine for their COVID-19 infection and 70%

these cases suggest that COVID-19 infection and likely the psycho-

were hospitalized.

logical and physiological stress surrounding the illness is capable of
inducing TE. As the pandemic continues, further studies will be
needed to understand the long-term prevalence and prognosis of TE
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DISCUSSION

associated with COVID-19 infection.

The presentations of these patients suggest that COVID-19 infection

CONFLIC T OF INT ER E ST

may be a significant trigger of TE, possibly due to psychosocial or

Henry Lim is a board member of the International League of Dermato-

physiologic stress. Most of these patients had a severe enough infec-

logical Societies that has provided partial support for the AAD-ILDS

tion that they required hospitalization and treatment with antibiotics,

COVID-19 Dermatology registry.

systemic corticosteroids, and/or hydroxychloroquine. In previous
studies, it has been reported that those with more severe COVID-19
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